{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:17:19Z","timestamp":1792783039385,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universitat de Les Illes Balears","id":[{"id":"https:\/\/ror.org\/03e10x626","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Care Anal"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-ageing medicines are products intended to extend lifespan and healthspan in humans that have a good potential use in public health policies. In the European Union, their development, production and consumption are dependent on regulatory science performed by the European Medicines Agency and its associated epistemic policies. They impose, among other things, an unfavourable burden of proof, a strict standard of proof and meta-methodological constrictions related to some theoretical issues. This results in a distribution of errors that tends to reduce false positives while increasing false negatives, leading to a set of social consequences that are generally accepted when the focus is placed on conventional medicines. However, when the same epistemic policies are applied to anti-ageing medicines, the distribution of errors is imbalanced, and undesirable outcomes like research discouragement and waiting time extensions appear. Three possible strategies that policymakers could implement to unblock the situation are presented for future reflection: the consideration of ageing as a disease, the application of methodological asymmetry and the use of biomarkers during clinical research.<\/jats:p>","DOI":"10.1007\/s10728-024-00497-9","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T03:43:02Z","timestamp":1731987782000},"page":"356-371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Epistemic Policies of Anti-Ageing Medicines in the European Union"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1022-6479","authenticated-orcid":false,"given":"Guillermo","family":"Mar\u00edn Penella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"497_CR1","unstructured":"Roser, M., Ortiz-Ospina, E., & Ritchie, H. (2013). Life expectancy. Our World in Data. Retrieved December 5, 2022, from https:\/\/ourworldindata.org\/life-expectancy"},{"key":"497_CR2","unstructured":"Sinclair, D., & LaPlante, M. (2019). Lifespan: why we age and why we don\u2019t have to. Thorsons."},{"key":"497_CR3","unstructured":"Stanford Centre on Longevity (2022). The new map of life. Stanford Centre on Longevity. Retrieved December 5, 2022, from https:\/\/longevity.stanford.edu\/the-new-map-of-life-full-report\/"},{"issue":"2","key":"497_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243\u2013278. https:\/\/doi.org\/10.1016\/j.cell.2022.11.001","journal-title":"Cell"},{"key":"497_CR5","doi-asserted-by":"publisher","unstructured":"Mishra, S. K., Balendra, V., Esposto, J., Obaid, A. A., Maccioni, R. B., Jha, N. K., Perry, G., Moustafa, M., Al-Sheri, M., Singh, M. P., Khan, A. A., Vamanu, E., & Singh, S. K. (2022). Therapeutic antiaging strategies. Biomedicines, 10(10). https:\/\/doi.org\/10.3390\/biomedicines10102515","DOI":"10.3390\/biomedicines10102515"},{"issue":"6","key":"497_CR6","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C L\u00f3pez-Ot\u00edn","year":"2013","unstructured":"L\u00f3pez-Ot\u00edn, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194\u20131217. https:\/\/doi.org\/10.1016\/j.cell.2013.05.039","journal-title":"Cell"},{"issue":"4","key":"497_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11357-018-0036-9","volume":"40","author":"M Kaeberlein","year":"2018","unstructured":"Kaeberlein, M. (2018). How healthy is the healthspan concept? GeroScience, 40(4), 361\u2013364. https:\/\/doi.org\/10.1007\/s11357-018-0036-9","journal-title":"GeroScience"},{"issue":"4","key":"497_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/acel.12338","volume":"14","author":"V Longo","year":"2015","unstructured":"Longo, V., et al. (2015). Interventions to slow aging in humans: Are we ready? Aging Cell, 14(4), 497\u2013510. https:\/\/doi.org\/10.1111\/acel.12338","journal-title":"Aging Cell"},{"key":"497_CR9","doi-asserted-by":"publisher","unstructured":"Nielsen, J. L., Bakula, D., & Scheibye-Knudsen, M. (2022). Clinical trials targeting aging. Frontiers in Aging, 3(820215). https:\/\/doi.org\/10.3389\/fragi.2022.820215","DOI":"10.3389\/fragi.2022.820215"},{"key":"497_CR10","doi-asserted-by":"publisher","unstructured":"Liu, J. K. (2022). Antiaging agents: Safe interventions to slow aging and healthy life span extension. Natural Products and Bioprospecting, 12(18). https:\/\/doi.org\/10.1007\/s13659-022-00339-y","DOI":"10.1007\/s13659-022-00339-y"},{"key":"497_CR11","doi-asserted-by":"crossref","unstructured":"Blagosklonny, M. (2014). Koschei the immortal and anti-aging drugs. Cell Death and Disease, 5. e1552","DOI":"10.1038\/cddis.2014.520"},{"issue":"1","key":"497_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2020.04.001","volume":"32","author":"AS Kulkarni","year":"2020","unstructured":"Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020). Benefits of metformin in attenuating the hallmarks of aging. Cell Metabolism, 32(1), 15\u201330. https:\/\/doi.org\/10.1016\/j.cmet.2020.04.001","journal-title":"Cell Metabolism"},{"key":"497_CR13","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/ncomms3192","volume":"4","author":"M Mart\u00edn-Montalvo","year":"2013","unstructured":"Mart\u00edn-Montalvo, M., et al. (2013). Metformin improves healthspan and lifespan in mice. Nature Communications, 4, 2192. https:\/\/doi.org\/10.1038\/ncomms3192","journal-title":"Nature Communications"},{"key":"497_CR14","unstructured":"Barzilai, N., & Mazin, A. (2021, June 29). Dr. Nir Barzilai: We Can Live Healthier for Longer. Lifespan.io. Retrieved December 1, 2023, from https:\/\/www.lifespan.io\/news\/dr-nir-barzilai-we-can-live-healthier-for-longer\/"},{"issue":"11","key":"497_CR15","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/dom.12354","volume":"16","author":"CA Bannister","year":"2014","unstructured":"Bannister, C. A., Holden, S. E., Jenkins-Jones, S., Morgan, C. L. I., Halcox, J. P., Schernthaner, G., Mukherjee, J., & Currie, C. J. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obesity and Metabolism, 16(11), 1165\u20131173. https:\/\/doi.org\/10.1111\/dom.12354","journal-title":"Diabetes Obesity and Metabolism"},{"issue":"7253","key":"497_CR16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","volume":"460","author":"A Bito","year":"2016","unstructured":"Bito, A., Ito, T. K., Pineda, V. V., LeTexier, N. J., Huang, H. Z., Sutlief, E., Tung, H., Vizzini, N., Chen, B., Smith, K., Meza, D., Yajima, M., Beyer, R. P., Kerr, K. F., Davis, D. J., Gillespie, C. H., Snyder, J. M., Treuting, P. M., & Kaeberlein, M. (2016). Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. Nature, 460(7253), 392\u2013395. https:\/\/doi.org\/10.1038\/nature08221","journal-title":"Nature"},{"issue":"3","key":"497_CR17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/acel.12194","volume":"13","author":"RA Miller","year":"2013","unstructured":"Miller, R. A., Harrison, D. E., Astle, C. M., Fernandez, E., Flurkey, K., Han, M., Javors, M. A., Li, X., Nadon, N. L., Nelson, J. F., Pletcher, S., Salmon, A. B., Sharp, Z. D., Van Roekel, S., Winkleman, L., & Strong, R. (2013). Rapamycin\u2013mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell, 13(3), 468\u2013477. https:\/\/doi.org\/10.1111\/acel.12194","journal-title":"Aging Cell"},{"key":"497_CR18","doi-asserted-by":"publisher","unstructured":"Zhang, Y., Bokov, A., Gelfand, J., Soto, V., Ikeno, Y., Hubbard, G., D\u00edaz, V., Sloane, L., Maslin, K., Treaster, S., R\u00e9ndon, S., van Remmen, H., Ward, W., Javors, M., Richardson, A., Austad, S. N., & Fischer, K. Rapamycin extends life and health in C57BL\/6 mice. The Journals of Gerontology Series A Biological Sciences and Medical Sciences, 69A(2), 119\u2013130. https:\/\/doi.org\/10.1093\/gerona\/glt056","DOI":"10.1093\/gerona\/glt056"},{"issue":"4","key":"497_CR19","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1016\/S2666-7568(21)00024-6","volume":"2","author":"E Bischof","year":"2021","unstructured":"Bischof, E., Scheibye-Knudsen, M., Siow, R., & Moskalev, A. (2021). Longevity medicine: Upskilling the physicians of tomorrow. Lancet Healthy Longevity, 2(4), e187\u2013e188. https:\/\/doi.org\/10.1016\/S2666-7568(21)00024-6","journal-title":"Lancet Healthy Longevity"},{"issue":"1561","key":"497_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1098\/rstb.2010.0288","volume":"366","author":"D Gems","year":"2011","unstructured":"Gems, D. (2011). Tragedy and delight: The ethics of decelerated ageing. Philosophical Transactions of the Royal Society, 366(1561), 108\u2013112. https:\/\/doi.org\/10.1098\/rstb.2010.0288","journal-title":"Philosophical Transactions of the Royal Society"},{"issue":"6209","key":"497_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1126\/science.1254405","volume":"346","author":"S Harper","year":"2014","unstructured":"Harper, S. (2014). Economic and social implications of aging societies. Science, 346(6209), 587\u2013591. https:\/\/doi.org\/10.1126\/science.1254405","journal-title":"Science"},{"issue":"2","key":"497_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3727\/194982414x14096821477027","volume":"16","author":"AA Moghissi","year":"2014","unstructured":"Moghissi, A. A., Straja, S. R., Love, B. R., Bride, D. K., & Stough, R. R. (2014). Innovation in regulatory science: Evolution of a new scientific discipline. Technology & Innovation, 16(2), 155\u2013165. https:\/\/doi.org\/10.3727\/194982414x14096821477027","journal-title":"Technology & Innovation"},{"key":"497_CR23","unstructured":"Jasanoff, S. (1990). The fifth branch. Science advisers as policymakers. Harvard University Press."},{"key":"497_CR24","unstructured":"Luj\u00e1n, J. L., & L\u00f3pez Cerezo, J. A. (2004). Innovaci\u00f3n tecnol\u00f3gica, riesgos e incertidumbres. Sobre La relaci\u00f3n entre conocimiento cient\u00edfico y las pol\u00edticas p\u00fablicas relacionadas con la tecnolog\u00eda. In J. L. Luj\u00e1n, & J. Echevarr\u00eda (Eds.), Gobernar Los riesgos: Ciencia Y valores de la sociedad del riesgo (pp. 75\u201398). Biblioteca Nueva."},{"issue":"1","key":"497_CR25","first-page":"167","volume":"39","author":"S Jasanoff","year":"2010","unstructured":"Jasanoff, S., Kurihara, C., & Saio, T. (2010). \u00bfWhat is the regulatory science? Concept and history in United States and in Japan. Clinical Evaluation, 39(1), 167\u2013180.","journal-title":"Clinical Evaluation"},{"key":"497_CR26","doi-asserted-by":"crossref","unstructured":"Luj\u00e1n, J. L., & Todt, O. (2018). Regulatory science: Between technology and society. In B. Laspra, J. A. L\u00f3pez, & Cerezo (Eds.), Spanish philosophy of Technology. Philosophy of Engineering and Technology (pp. 59\u201372). Springer.","DOI":"10.1007\/978-3-319-71958-0_5"},{"key":"497_CR27","unstructured":"L\u00f3pez-Mas, R. (2022). Est\u00e1ndares de prueba en la ciencia reguladora: jerarqu\u00edas evidenciales y pluralismo metodol\u00f3gico. TESEO. Retrieved April 12, 2020, from https:\/\/www.educacion.gob.es\/teseo\/imprimirFicheroTesis.do?idFichero=mrvft0iZyC4%3D"},{"key":"497_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jmst.2022.04.018","volume":"128","author":"X Song","year":"2022","unstructured":"Song, X., Tang, Z., Liu, W., Chen, K., Liang, J., Yuan, B., Lin, H., Zhu, X., Fan, Y., Shi, X., Zhao, P., Yang, L., Zhang, K., Mikos, A. G., & Zhang, X. (2022). Biomaterials and regulatory science. Journal of Materials Science and Technology, 128, 221\u2013227. https:\/\/doi.org\/10.1016\/j.jmst.2022.04.018","journal-title":"Journal of Materials Science and Technology"},{"key":"497_CR29","unstructured":"EMA (2020). EMA regulatory science to 2025 strategic reflection. EMA. Retrieved March 14, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf"},{"issue":"4","key":"497_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/02691728.2021.2004467","volume":"36","author":"N Sanz Merino","year":"2022","unstructured":"Sanz Merino, N. (2022). Policy styles and epistemic policies in the regulation of health claims. A comparison of Europe, the United States, and Japan. Social Epistemology, 36(4), 449\u2013465. https:\/\/doi.org\/10.1080\/02691728.2021.2004467","journal-title":"Social Epistemology"},{"key":"497_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.21308\/recp.55.04","volume":"55","author":"N Sanz Merino","year":"2021","unstructured":"Sanz Merino, N., & Luj\u00e1n, J. L. (2021). Pol\u00edticas epist\u00e9micas y gobernanza. Un an\u00e1lisis comparativo de las regulaciones norteamericana y europea sobre declaraciones de propiedades saludables. Revista Espa\u00f1ola De Ciencia Politica, 55, 93\u2013117. https:\/\/doi.org\/10.21308\/recp.55.04","journal-title":"Revista Espa\u00f1ola De Ciencia Politica"},{"key":"497_CR32","unstructured":"Luj\u00e1n, J. L., & Todt, O. (2022). Controversias en ciencia reguladora: cuatro ejemplos y una propuesta de an\u00e1lisis. In Proceedings of the XIV Congreso Espa\u00f1ol de Sociolog\u00eda (p. 134)."},{"key":"497_CR33","doi-asserted-by":"publisher","unstructured":"Luj\u00e1n, J. L., & Todt, O. (2021). Evidence based methodology: A naturalistic analysis of epistemic policies in regulatory science. European Journal for Philosophy of Science, 11(26). https:\/\/doi.org\/10.1007\/s13194-020-00340-7","DOI":"10.1007\/s13194-020-00340-7"},{"issue":"4","key":"497_CR34","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/13669877.2015.1100661","volume":"20","author":"O Todt","year":"2017","unstructured":"Todt, O., & Luj\u00e1n, J. L. (2017). The role of epistemic policies in regulatory science: Scientific substantiation of health claims in the European Union. Journal of Risk Research, 20(4), 551\u2013565. https:\/\/doi.org\/10.1080\/13669877.2015.1100661","journal-title":"Journal of Risk Research"},{"key":"497_CR35","doi-asserted-by":"crossref","unstructured":"Douglas, H. (2007). Rejecting the ideal of value free science. In H. Kincaid, J. Dupr\u00e9, & A. Wylie (Eds.), Value free science? Ideas and illusions (pp. 120\u2013140). Oxford University Press.","DOI":"10.1093\/acprof:oso\/9780195308969.003.0009"},{"issue":"3","key":"497_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.shpsa.2013.06.003","volume":"44","author":"KC Elliot","year":"2013","unstructured":"Elliot, K. C. (2013). Douglas on values: From indirect roles to multiple goals. Studies in History and Philosophy of Science, 44(3), 375\u2013383. https:\/\/doi.org\/10.1016\/j.shpsa.2013.06.003","journal-title":"Studies in History and Philosophy of Science"},{"issue":"2","key":"497_CR37","first-page":"123","volume":"8","author":"CF Cranor","year":"1997","unstructured":"Cranor, C. F. (1997). The normative nature of risk assessment: Features and possibilities. RISK, 8(2), 123\u2013136.","journal-title":"RISK"},{"key":"497_CR38","unstructured":"European Commission (2001). Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. EUR-Lex. Retrieved December 27, 2022, from https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32001L0083"},{"key":"497_CR39","unstructured":"EMA. (2009). ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. EMA. Retrieved December 17, 2022, from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m3r2-non-clinical-safety-studies-conduct-human-clinical-trials-marketing-authorisation_en.pdf"},{"key":"497_CR40","unstructured":"EMA. (n.d.). Clinical trials in human medicines. EMA. Retrieved March 31 (2023). from https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/clinical-trials-human-medicines"},{"key":"497_CR41","unstructured":"EMA (1998). ICH topic E 9 statistical principles for clinical trials. EMA. Retrieved December 19, 2022, from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf"},{"key":"497_CR42","unstructured":"EMA (2022). EMA Medical terms simplifier. EMA. Retrieved January 14, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/other\/ema-medical-terms-simplifier_en.pdf"},{"issue":"1","key":"497_CR43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.2479","volume":"111","author":"P Arlett","year":"2022","unstructured":"Arlett, P., Kjeaer, J., Broich, K., & Cooke, E. (2022). Real-world evidence in EU medicines regulation: Enabling use and establishing value. Clinical Pharmacology & Therapeutics, 111(1), 21\u201323. https:\/\/doi.org\/10.1002\/cpt.2479","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"e011666","key":"497_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2016","volume":"6","author":"AJ Hatswell","year":"2016","unstructured":"Hatswell, A. J., Baio, G., Berlin, J. A., Irs, A., & Freemantle, N. (2016). Regulatory approval of pharmaceuticals without a randomised controlled study: Analysis of EMA and FDA approvals 1999\u20132014. British Medical Journal, 6(e011666), 1\u20138. https:\/\/doi.org\/10.1136\/bmjopen-2016","journal-title":"British Medical Journal"},{"issue":"6","key":"497_CR45","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/clpt.2010.207","volume":"88","author":"WPC Boon","year":"2010","unstructured":"Boon, W. P. C., Moors, E. H. M., Meijer, A., & Schellekens, H. (2010). Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clinical Pharmacology and Therapeutics, 88(6), 848\u2013853. https:\/\/doi.org\/10.1038\/clpt.2010.207","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"497_CR46","unstructured":"EMA. (n.d.). Conditional marketing authorisation. EMA. Retrieved April 2 (2023). from https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/conditional-marketing-authorisation"},{"key":"497_CR47","unstructured":"EMA. (n.d.). Exceptional circumstances. EMA. Retrieved April 3 (2023). from https:\/\/www.ema.europa.eu\/en\/glossary\/exceptional-circumstances"},{"key":"497_CR48","unstructured":"CHMP (2021). Assessment report. Comirnaty. Procedure No. EMEA\/H\/C\/005735\/0000. CHMP. Retrieved April 3, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/comirnaty-epar-public-assessment-report_en.pdf"},{"key":"497_CR49","unstructured":"CHMP (2021). Assessment report. Covid-19 vaccine AstraZeneca. Procedure No. EMEA\/H\/C\/005675\/0000. CHMP. Retrieved March 31, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf"},{"key":"497_CR50","unstructured":"CHMP. (2009). Assessment report. Vedrop. Procedure No. EMEA\/H\/C\/000920. CHMP. Retrieved April 4, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vedrop-epar-public-assessment-report_en.pdf"},{"key":"497_CR51","unstructured":"CHMP (2014). Assessment report. Scenesse. Procedure No. EMEA\/H\/C\/002548\/0000. CHMP. Retrieved April 4, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/scenesse-epar-public-assessment-report_en.pdf"},{"key":"497_CR52","unstructured":"CHMP (2014). Assessment report. Translarna. Procedure No. EMEA\/H\/C\/002720. CHMP. Retrieved April 4, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/translarna-epar-public-assessment-report_en.pdf"},{"key":"497_CR53","unstructured":"CHMP (2022). Assessment report. Kinpeygo. Procedure No. EMEA\/H\/C\/005653\/0000. CHMP. Retrieved April 4, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/kinpeygo-epar-public-assessment-report_en.pdf"},{"issue":"2","key":"497_CR54","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11245-013-9189-4","volume":"33","author":"J Stegenga","year":"2014","unstructured":"Stegenga, J. (2014). Down with the hierarchies. Topoi, 33(2), 313\u2013322. https:\/\/doi.org\/10.1007\/s11245-013-9189-4","journal-title":"Topoi"},{"key":"497_CR55","unstructured":"European Commission (2004). Regulation (EC) No 726\/2004 of the European Parliament and of the Council of 21 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. EUR-Lex. Retrieved December 27, 2022, from https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32004R0726"},{"key":"497_CR56","unstructured":"EMA (2019). From laboratory to patient - the journey of a medicine assessed by EMA. EMA. Retrieved February 14, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/other\/laboratory-patient-journey-centrally-authorised-medicine_en.pdf"},{"key":"497_CR57","unstructured":"European Commission (2010). Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. EUR-Lex. Retrieved March 18, 2023, from https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF"},{"key":"497_CR58","unstructured":"World Medical Association (2018). Declaration of Helsinki - Ethical principles for medical research involving human subjects. World Medical Association. Retrieved March 28, 2023, from https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/"},{"key":"497_CR59","unstructured":"EMA. (n.d.). Medicinal product. EMA. Retrieved March 20 (2023). from https:\/\/www.ema.europa.eu\/en\/glossary\/medicinal-product"},{"key":"497_CR60","unstructured":"EMA. (n.d.). Indication. EMA, & Retrieved (2023). March 20, from https:\/\/www.ema.europa.eu\/en\/glossary\/indication"},{"key":"497_CR61","unstructured":"World Health Organization (2022). IDC-11 for mortality and morbidity statistics. World Health Organization. Retrieved April 6, 2023, from https:\/\/icd.who.int\/browse11\/l-m\/en#\/http:\/\/id.who.int\/icd\/entity\/835503193"},{"key":"497_CR62","unstructured":"Straus, S. E., Glasziou, P., Richardson, S. W., Haynes, B. R., Pattani, R., & Angeliki, V., A (2019). Evidence-based medicine: How to practice and teach EBM. Elsevier."},{"issue":"13","key":"497_CR63","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/1471-0528.15199","volume":"125","author":"E Hariton","year":"2018","unstructured":"Hariton, E., & Locascio, J. J. (2018). Randomised controlled trials\u2013 the gold standard for effectiveness research. BJOG An International Journal of Obstetrics and Gyneacology, 125(13), 1716. https:\/\/doi.org\/10.1111\/1471-0528.15199","journal-title":"BJOG An International Journal of Obstetrics and Gyneacology"},{"issue":"1","key":"497_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-017-2099-9","volume":"18","author":"S Djurisic","year":"2017","unstructured":"Djurisic, S., Rath, A., Gaber, S., Garattini, S., Bertele, V., Ngwabyt, S. N., Hivert, V., Neugebauer, E. A. M., Laville, M., Hiesmayr, M., Demotes-Mainard, J., Kubiak, C., Jakobsen, J. C., & Gluud, C. (2017). Barriers to the conduct of randomised clinical trials within all disease areas. Trials, 18(1), 1\u201310. https:\/\/doi.org\/10.1186\/s13063-017-2099-9","journal-title":"Trials"},{"issue":"4","key":"497_CR65","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1017\/S0266462320000355","volume":"36","author":"P Pinilla-Dominguez","year":"2020","unstructured":"Pinilla-Dominguez, P., Naci, H., Osipenko, L., & Mossialos, E. (2020). NICE\u2019s evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances. International Journal of Technology Assessment in Health Care, 36(4), 426\u2013433. https:\/\/doi.org\/10.1017\/S0266462320000355","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"3","key":"497_CR66","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11357-020-00274-1","volume":"43","author":"R Selvarani","year":"2021","unstructured":"Selvarani, R., Mohammed, S., & Richardson, A. (2021). Effect of rapamycin on aging and age-related diseases\u2014past and future. GeroScience, 43(3), 1135\u20131358. https:\/\/doi.org\/10.1007\/s11357-020-00274-1","journal-title":"GeroScience"},{"issue":"4","key":"497_CR67","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2337\/dc11-1299","volume":"35","author":"The Diabetes Prevention Research Group","year":"2012","unstructured":"The Diabetes Prevention Research Group. (2012). Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care, 35(4), 731\u2013737. https:\/\/doi.org\/10.2337\/dc11-1299","journal-title":"Diabetes Care"},{"key":"497_CR68","unstructured":"CHMP (2016). Assessment report. Metformin containing medicinal products. Procedure No. EMEA\/H\/A-31\/1432. CHMP. Retrieved March 31, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/referral\/metformin-article-31-referral-chmp-assessment-report_en.pdf"},{"key":"497_CR69","unstructured":"CHMP. Rapamune. Assessment report. Procedure No. EMEA\/H\/C\/000273\/II\/0164. Retrieved, C. H. M. P. (2018). March 25, 2023, from https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/rapamune-h-c-273-ii-0164-epar-assessment-report-variation_en.pdf"},{"key":"497_CR70","unstructured":"Rae, M. (2023). A TAME attempt to slow aging part 5: Winning the game with a weak hand. SENS Research Foundation. Retrieved April 1, 2023, from https:\/\/www.sens.org\/tame-attempt-slow-aging-part-5-metformin-win-game-weak-hand\/"},{"issue":"11","key":"497_CR71","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.tibtech.2017.07.004","volume":"35","author":"JP De Magalh\u00e3es","year":"2017","unstructured":"De Magalh\u00e3es, J. P., Stevens, M., & Thornton, D. (2017). The business of anti-aging science. Trends in Biotechnology, 35(11), 1062\u20131073. https:\/\/doi.org\/10.1016\/j.tibtech.2017.07.004","journal-title":"Trends in Biotechnology"},{"issue":"6","key":"497_CR72","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/jmp\/jhac030","volume":"47","author":"C Saborido","year":"2022","unstructured":"Saborido, C., & Garc\u00eda-Barranquero, P. (2022). Is aging a disease? The theoretical definition of aging in the light of the philosophy of medicine. The Journal of Medicine and Philosophy, 47(6), 770\u2013783. https:\/\/doi.org\/10.1093\/jmp\/jhac030","journal-title":"The Journal of Medicine and Philosophy"},{"issue":"2","key":"497_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00002512-199813020-00001","volume":"13","author":"D Callahan","year":"1998","unstructured":"Callahan, D., & Topinkova, E. (1998). Is aging a preventable or curable disease? Drugs & Aging, 13(2), 93\u201397.","journal-title":"Drugs & Aging"},{"issue":"3","key":"497_CR74","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/jep.12039","volume":"19","author":"B Osimani","year":"2013","unstructured":"Osimani, B. (2013). Until RCT proven? On the asymmetry of evidence requirements for risk assessment. Journal of Evaluation in Clinical Practice, 19(3), 454\u2013462. https:\/\/doi.org\/10.1111\/jep.12039","journal-title":"Journal of Evaluation in Clinical Practice"},{"issue":"2","key":"497_CR75","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/02698590701498084","volume":"21","author":"F Russo","year":"2007","unstructured":"Russo, F., & Williamson, J. (2007). Interpreting causality in the health sciences. International Studies in the Philosophy of Science, 21(2), 157\u2013170. https:\/\/doi.org\/10.1080\/02698590701498084","journal-title":"International Studies in the Philosophy of Science"},{"issue":"6","key":"497_CR76","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1177\/0162243919828070","volume":"44","author":"M Andreoletti","year":"2019","unstructured":"Andreoletti, M., & Teira, D. (2019). Rules versus standards: What are the costs of epistemic norms in drug regulation? Science Technology and Human Values, 44(6), 1093\u20131115. https:\/\/doi.org\/10.1177\/0162243919828070","journal-title":"Science Technology and Human Values"},{"key":"497_CR77","doi-asserted-by":"crossref","unstructured":"Teira, D. (2020). On the normative foundations of pharmaceutical regulation. In A. LaCaze, & B. Osimani (Eds.), Uncertainty in Pharmacology (pp. 417\u2013438). Springer.","DOI":"10.1007\/978-3-030-29179-2_18"},{"key":"497_CR78","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0531-5565(88)90025-3","volume":"23","author":"G Baker","year":"1988","unstructured":"Baker, G., & Sprott, R. (1988). Biomarkers of aging. Experimental Gerontology, 23, 223\u2013239.","journal-title":"Experimental Gerontology"},{"issue":"1","key":"497_CR79","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/tsq.12079","volume":"56","author":"T Moreira","year":"2015","unstructured":"Moreira, T. (2015). Unsettling standards: The biological age controversy. Sociological Quarterly, 56(1), 18\u201339. https:\/\/doi.org\/10.1111\/tsq.12079","journal-title":"Sociological Quarterly"},{"key":"497_CR80","unstructured":"ICH (1998). ICH harmonised tripartite guideline: Statistical principles for clinical trials E9. ICH Harmonisation for better health. Retrieved April 10, 2024, from https:\/\/database.ich.org\/sites\/default\/files\/E9_Guideline.pdf"}],"container-title":["Health Care Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10728-024-00497-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10728-024-00497-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10728-024-00497-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:48:39Z","timestamp":1792144119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10728-024-00497-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1007\/s10728-024-00497-9","relation":{},"ISSN":["1065-3058","1573-3394"],"issn-type":[{"value":"1065-3058","type":"print"},{"value":"1573-3394","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"1 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}